Cancer Research UK on Google+ Cancer Research UK on Facebook Cancer Research UK on Twitter
Skip navigation

A trial looking at denosumab for early breast cancer (D-CARE)

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

This trial is trying to find out if denosumab can stop or delay breast cancer spreading to the bones. It is for women who have early breast cancer and their doctors think there is a high risk of it coming back or spreading to their bones.

Doctors treat early breast cancer with surgery, radiotherapy, hormone therapy, chemotherapy or biological therapy. Most women begin treatment with surgery to remove their cancer. But they often have one or more other treatments to lower the chance of the cancer coming back in the breast, or spreading elsewhere in the body. This is called adjuvant therapy.

In this trial, researchers are looking at a drug called denosumab as adjuvant therapy. It is a type of biological therapy called a monoclonal antibody. Denosumab may help to stop breast cancer spreading to the bones.

The aims of the study are to

  • See if having denosumab, as well as standard treatment for early breast cancer, can stop the cancer spreading to the bones, or increase the length of time before this happens
  • Learn more about the side effects

Recruitment

Start 01/09/2010
End 23/08/2012

Phase

Phase 3

Who can enter

You can enter this trial if you

  • Have breast cancer that is stage 2 or 3
  • Have cancer that your doctors think has a high risk of coming back – this may be because you have cancer cells in the lymph nodes under your arm, or the tumour is larger than 5cm across or has grown into the skin or chest wall (stage T3 or T4)
  • Have had, or are going to have surgery to completely remove your breast cancer as well as having standard treatments to reduce the risk of cancer coming back – these may include chemotherapy, hormone therapy or biological therapy before or after surgery
  • Have satisfactory blood test results
  • Are well enough to carry out all your normal activities, apart from heavy physical work (performance status of 0 or 1)
  • Are willing to use reliable methods of contraception during the trial treatment and for 7 months afterwards if there is any chance you could become pregnant
  • Are female and at least 18 years old

You cannot enter this trial if you

  • Have cancer that has spread to another part of your body (metastatic cancer)
  • Have had breast cancer in the past – you can still take part if you have had ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS)
  • Have osteoporosis that is being treated or that your doctor thinks is likely to need treating soon
  • Have ever had an infection in the bone (osteomyelitis) or a rare condition called osteonecrosis of the jaw
  • Need to have surgery to your teeth or mouth, or you have had surgery to your teeth or mouth and it has not healed up yet
  • Have ever had drugs called bisphosphonates through a drip into a vein, or have taken any bisphosphonate drugs by mouth in the last year
  • Have ever had denosumab
  • Have had an experimental drug as part of another clinical trial in the last month
  • Have any other medical condition that the trial doctors think would affect you taking part in this trial
  • Are pregnant or breastfeeding

Trial design

The trial will recruit about 4,500 people in a number of countries around the world. It is a randomised trial. The people taking part are put into 1 of 2 treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in. And neither you nor your doctor will know which group you are in either. This is called a double blind trial.

  • People in group 1 have denosumab as an injection under the skin (subcutaneous injection) once a month for 6 months and then once every 3 months for the next 4 and a half years
  • People in group 2 have injections in the same way, but they are a dummy drug (placebo)

Everybody taking part in the study will take vitamin D and calcium supplements every day. Your doctor will prescribe these for you free of charge.

If you have already had surgery to remove your cancer, the researchers will get a sample of the cancer tissue removed. They will study this, along with blood samples, to learn more about how characteristics of your tumour or certain genes may affect the way breast cancer grows and how people respond to denosumab.

The researchers will use some of your blood and cancer tissue samples to look for biomarkers. These are substances in the body that doctors can measure to help them tell how a disease is developing or how a treatment is working. They hope that in the future, biomarkers may help them to work out who is most likely to benefit from denosumab.

If results from this trial show that denosumab helps to stop cancer spreading to the bones, any woman still having treatment will be able to have denosumab for the remainder of their 5 years of treatment. If the results show that denosumab does not help, then all women will stop taking study treatment. In that case, your doctor will talk to you about other possible treatment options that are available.

Hospital visits

You will see a doctor and have some tests before you start treatment. The tests include

You will go to the hospital every 3 or 4 weeks for the first 6 months and then every 3 months for the next 4 and a half years. You will have blood tests and an injection under the skin each time. These visits will last about 1 to 2 hours. Every 6 months, you will have an examination of your mouth to check that your mouth and jaw are healthy. And every 3 months, the trial team will ask you to give a urine sample.

Every year during the trial treatment you will have a

  • Bone scan
  • CT scan or MRI
  • Mammogram

After you finish treatment, the trial team will see you at the hospital one more time, and you have more tests and scans. This visit will take 2 to 3 hours. For the next 6 months after this visit the trial team will contact you by phone or see you at the hospital once a month. These phone calls should take no more than about 15 minutes.

After 6 months, you will have another blood test at the hospital. After this, a member of the trial team will contact you every 3 or 6 months to see how you are doing. You may also have bone scans and CT or MRI scans once a year.

Side effects

As denosumab is still quite a new drug, there may be some side effects we don’t know about yet. From earlier trials, we know the possible side effects include

  • Low levels of calcium in the blood which can cause tingling or muscle cramps (you take calcium and vitamin D supplements to help stop this happening)
  • Osteonecrosis of the jaw
  • Skin infections

Location of trial

CLOSED

For more information

Please note: we cannot help you to join a specific trial. Unless we state otherwise in this trial summary, you need to print this page and take it to your own doctor to discuss.

Find out how to join a trial or contact our cancer information nurses for other questions about cancer by phone (0808 800 4040), by email, or at

The Information Nurses
Cancer Research UK
Angel Building
407 St John Street
London
EC1V 4AD

Chief Investigator

Professor Robert Coleman

Supported by

Amgen
Experimental Cancer Medicine Centre (ECMC)
National Institute for Health Research Cancer Research Network (NCRN)
Rate this page:
Submit rating
Rate this page
Rate this page for no comments box
Please enter feedback to continue submitting
Send feedback
Question about cancer? Contact our information nurse team

No Error

Updated: 23 August 2012